A randomized clinical trial to evaluate solutions for the management of virologic failure for individuals on TLD in sub-saharan africa
Active Project Grant Awarded Last action
- Award ID
- R01AI167699
- Recipient
-
The General Hospital Corporation UEI FLJ7DQKLL226
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,515,331
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 86% complete
- Place of performance
- Boston, MA 02114, USA
Award details come from USAspending.gov.
Description
- Abstract
- Significance: tenofovir, lamivudine, and dolutegravir (TLD) has become the predominant first-line antiretroviral therapy (art) regimen in sub-saharan africa (SSA). While virologic failure on TLD is relatively rare currently, rates will inevitably increase over time, threatening epidemic control in the region. The optimal management of virologic failure on TLD is currently unknown, and policies vary widely in SSA. Innovation: we propose the first randomized clinical trial to determine the optimal management strategy for virologic failure on TLD in SSA. The trial will evaluate a novel individualized care strategy, which seeks to address diverse patient- level determinants of virologic failure, including adherence challenges, pill burden, patient preference, regimen tolerability, and drug resistance. The individualized care strategy incorporates a point-of-care urine tenofovir assay, as well as genotypic resistance tests, with a goal of salvaging once-daily regimens among individuals with virologic failure on TLD. Investigators: our expert team of clinical epidemiologists (suzanne mccluskey), implementation scientists and clinical trialists (mark siedner, monica gandhi), global partners (winnie muyindike, richard lessells, mahomed yunus moosa), biostatisticians (susanne hoeppner), and decision scientists (emily hyle), led by an early-stage investigator (mccluskey), is uniquely positioned to provide policy- guiding data in response to this question of great public health significance. Approach: we will leverage an established pragmatic clinical trial infrastructure which recently completed an NIH R01-funded randomized trial in mbarara, uganda and durban, south africa to complete the following specific aims: aim 1) we will conduct the resolve trial, an open, parallel arm, randomized clinical trial in six public sector clinics to determine the optimal strategy for management of virologic failure on first-line TLD in SSA. We will randomize participants to one of the following strategies: a) maintenance on TLD with switch to protease inhibitor (PI)- based second-line art if virologic failure persists past six months, similar to current guidelines in south africa; b) individualized care, with regimen choice based on results of genotypic resistance tests and urine tenofovir assays; or c) immediate switch to PI-based second-line art, similar to current guidelines in uganda. The primary outcome will be viral suppression (
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $170,440 | |
| Amendment | $197,189 | |
| Amendment | $400,727 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $138,865 | |
| Amendment | $278,479 | |
| Amendment | $248,084 | |
| Amendment | $643,482 | |
| Amendment | $648,976 | |
| Amendment | $694,181 | |
| Original award | $694,181 |
Show all 14
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Mbarara University Of Science And Technology | $309,304 | |
| Adrenergy Research Innovations (Pty) LTD | $411,235 | |
| The Regents Of The University Of California. San Francisco | $53,709 | |
| Mbarara University Of Science And Technology | $335,770 | |
| Adrenergy Research Innovations (Pty) LTD | $539,164 |
Quick answers
Who received award R01AI167699?
R01AI167699 was awarded to The General Hospital Corporation by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 1, 2022.
How much is award R01AI167699 worth?
$4,515,331 has been obligated on R01AI167699.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award